EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

FAT1 Is Differentially Expressed in Cancers Affecting the Serosal Cavities

Ben Davidson, Arild Holth

Pathobiology · 27.03.2026 · 1-8

DOI: 10.1159/000551734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathobiology, online erschienen am 27.03.2026. Verfasst von Ben Davidson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway, bend@medisin.uio.no. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

FAT1 is mutated in many types of cancer. The objective of this study was to analyze the diagnostic role of FAT1 protein in cancers affecting the serosal cavities.

Methods

FAT1 protein expression by immunohistochemistry was analyzed in 256 effusions (139 peritoneal, 116 pleural, 1 pericardial), consisting of 96 tubo-ovarian carcinomas, 56 breast carcinomas, 44 mesotheliomas, 28 uterine corpus and cervical carcinomas, 15 lung carcinomas, 13 gastrointestinal carcinomas, and 4 cancers of other origin.

Results

FAT1 expression was most common in gastrointestinal carcinomas (12/13; 92%), followed by lung (9/15; 60%), breast (31/56; 55%), and uterine cervical (4/8; 50%) carcinomas, with infrequent expression in other tumors, including tubo-ovarian carcinomas (5/96; 5%). Mesotheliomas were uniformly negative. Staining of a limited series of surgical specimens showed comparable results for patient-matched breast carcinomas (29/41; 71%), whereas tubo-ovarian carcinomas were more frequently positive (16/57; 28%), though often focally, compared to effusions. Eight epithelioid mesotheliomas were negative (0/8; 0%). Survival analysis for 42 breast carcinoma patients with effusion for whom clinical data were available showed no association with overall (p = 0.398) or disease-free (p = 0.255) survival.

Conclusion

FAT1 is commonly expressed in carcinomas of gastrointestinal, lung, or breast origin but is rarely expressed in tubo-ovarian carcinoma effusions and is absent in mesothelioma. Whether this difference is of use in the diagnostic setting remains to be established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorNeoplasmsHumansFemaleImmunohistochemistryMiddle AgedMaleAgedAdultCadherins

Stichwörter der Autor:innen

DiagnosisEffusionFAT1Immunohistochemistry

Substanzen

FAT1 protein, humanBiomarkers, TumorCadherins

Autor:innen und Institutionen

  • Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway, bend@medisin.uio.no.
  • Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, bend@medisin.uio.no.
  • Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.

Zitieren

APA

Davidson, B., & Holth, A. (2026). FAT1 Is Differentially Expressed in Cancers Affecting the Serosal Cavities. Pathobiology, 1-8. https://doi.org/10.1159/000551734

Vancouver

Davidson B, Holth A. FAT1 Is Differentially Expressed in Cancers Affecting the Serosal Cavities. Pathobiology. 2026:1-8. doi:10.1159/000551734

BibTeX
@article{Davidson2026,
  author = {Davidson, Ben and Holth, Arild},
  title = {FAT1 Is Differentially Expressed in Cancers Affecting the Serosal Cavities},
  journal = {Pathobiology},
  year = {2026},
  pages = {1--8},
  doi = {10.1159/000551734}
}
Kostenlos starten →